Cardiotoxicity
Welcome,         Profile    Billing    Logout  
 10 Companies   21 Products   21 Products   0 Mechanisms of Action   15 Trials   128 News 


12»
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change, Trial primary completion date:  CaTOB: Cardiac Toxicity in Medical Treatment of Breast Cancer (clinicaltrials.gov) -  May 1, 2019   
    P=N/A,  N=45, Completed, 
    Recruiting --> Completed | N=70 --> 45 | Trial primary completion date: Dec 2017 --> Aug 2018
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Cardiotoxicity of Radiation Therapy (CTRT) (clinicaltrials.gov) -  Jan 9, 2019   
    P=N/A,  N=147, Completed, 
    Recruiting --> Completed | N=70 --> 45 | Trial primary completion date: Dec 2017 --> Aug 2018 Active, not recruiting --> Completed
  • ||||||||||  Trial completion date, Trial termination, Trial primary completion date:  Early Detection of Cardiac Toxicity in Childhood Cancer Survivors (clinicaltrials.gov) -  Dec 4, 2018   
    P=N/A,  N=42, Terminated, 
    Active, not recruiting --> Completed Trial completion date: Dec 2020 --> Mar 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Mar 2018; IRB approval expired
  • ||||||||||  Enrollment change, Trial completion date, Trial initiation date, Trial termination, Trial primary completion date:  CORE: Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity (clinicaltrials.gov) -  Oct 12, 2018   
    P=N/A,  N=2, Terminated, 
    Trial completion date: Dec 2020 --> Mar 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Mar 2018; IRB approval expired N=38 --> 2 | Trial completion date: Apr 2019 --> May 2018 | Initiation date: Nov 2017 --> Apr 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018; Limited recruitment
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment closed, Enrollment change, Trial primary completion date:  Cardiotoxicity of Radiation Therapy (CTRT) (clinicaltrials.gov) -  Oct 2, 2018   
    P=N/A,  N=147, Active, not recruiting, 
    N=38 --> 2 | Trial completion date: Apr 2019 --> May 2018 | Initiation date: Nov 2017 --> Apr 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018; Limited recruitment Recruiting --> Active, not recruiting | N=100 --> 147 | Trial primary completion date: Apr 2017 --> Dec 2018
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin (clinicaltrials.gov) -  Aug 21, 2018   
    P=N/A,  N=12, Completed, 
    Recruiting --> Active, not recruiting | N=100 --> 147 | Trial primary completion date: Apr 2017 --> Dec 2018 Recruiting --> Completed | N=150 --> 12 | Trial completion date: Jun 2018 --> Feb 2018 | Trial primary completion date: Jun 2018 --> Feb 2018
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date:  Breast Cancer Long-term Outcome of Cardiac Dysfunction (clinicaltrials.gov) -  Jun 15, 2018   
    P=N/A,  N=700, Completed, 
    Recruiting --> Completed | N=150 --> 12 | Trial completion date: Jun 2018 --> Feb 2018 | Trial primary completion date: Jun 2018 --> Feb 2018 Recruiting --> Completed | Trial completion date: Nov 2016 --> Oct 2017
  • ||||||||||  carvedilol / Generic mfg.
    Trial completion, Trial initiation date, Trial primary completion date:  Ceccy: Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity (clinicaltrials.gov) -  Feb 5, 2018   
    P3,  N=200, Completed, 
    Recruiting --> Completed | N=200 --> 133 Recruiting --> Completed | Initiation date: Jun 2012 --> Apr 2013 | Trial primary completion date: Oct 2016 --> Jun 2017
  • ||||||||||  Trial primary completion date:  CaTOB: Cardiac Toxicity in Medical Treatment of Breast Cancer (clinicaltrials.gov) -  Apr 6, 2017   
    P=N/A,  N=70, Recruiting, 
    Initiation date: Jan 2016 --> Apr 2015 Trial primary completion date: Jun 2017 --> Dec 2017
  • ||||||||||  Enrollment change, Trial initiation date, Trial withdrawal:  Cardiac 3D MRI in Pediatric Cancer Patients (clinicaltrials.gov) -  Nov 15, 2016   
    P=N/A,  N=0, Withdrawn, 
    Active, not recruiting --> Completed N=20 --> 0 | Initiation date: May 2015 --> May 2014 | Not yet recruiting --> Withdrawn
  • ||||||||||  Enrollment change:  Cardiotoxicity of Radiation Therapy (CTRT) (clinicaltrials.gov) -  Sep 7, 2016   
    P=N/A,  N=100, Recruiting, 
    N=20 --> 0 | Initiation date: May 2015 --> May 2014 | Not yet recruiting --> Withdrawn N=50 --> 100
  • ||||||||||  Enrollment change, Trial initiation date, Trial termination:  Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX) (clinicaltrials.gov) -  Aug 22, 2016   
    P=N/A,  N=6, Terminated, 
    Suspended --> Recruiting N=40 --> 6 | Initiation date: Oct 2005 --> Jan 2006 | Not yet recruiting --> Terminated; No patients; only 6 enrolled after 2 years
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Trial primary completion date, IO biomarker:  Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients (clinicaltrials.gov) -  May 13, 2016   
    P=N/A,  N=50, Suspended, 
    N=40 --> 6 | Initiation date: Oct 2005 --> Jan 2006 | Not yet recruiting --> Terminated; No patients; only 6 enrolled after 2 years Trial primary completion date: Mar 2016 --> Aug 2016
  • ||||||||||  New trial:  Cardiotoxicity of Radiation Therapy (CTRT) (clinicaltrials.gov) -  May 11, 2016   
    P=N/A,  N=50, Recruiting, 
  • ||||||||||  Trial completion, Trial primary completion date:  Cardiac Assessment of Patients With Hip Implants (clinicaltrials.gov) -  Apr 6, 2016   
    P=N/A,  N=90, Completed, 
    Trial primary completion date: Mar 2016 --> Aug 2016 Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Apr 2015
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Enrollment change, Trial suspension, Trial primary completion date, IO biomarker:  Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients (clinicaltrials.gov) -  Mar 31, 2016   
    P=N/A,  N=50, Suspended, 
    Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Apr 2015 N=100 --> 50 | Recruiting --> Suspended | Trial primary completion date: Dec 2015 --> Mar 2016
  • ||||||||||  carvedilol / Generic mfg.
    Trial primary completion date:  Ceccy: Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity (clinicaltrials.gov) -  Mar 8, 2016   
    P3,  N=200, Recruiting, 
    N=100 --> 50 | Recruiting --> Suspended | Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Jun 2016 --> Oct 2016
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion, Enrollment change, Trial primary completion date:  ASPER: Early Detection of Broken Hearts in Cancer Patients (clinicaltrials.gov) -  Jan 30, 2016   
    P=N/A,  N=43, Completed, 
    Recruiting --> Completed Recruiting --> Completed | N=100 --> 43 | Trial primary completion date: Dec 2015 --> Sep 2015
  • ||||||||||  Trial primary completion date:  Breast Cancer Long-term Outcome of Cardiac Dysfunction (clinicaltrials.gov) -  Dec 4, 2015   
    P=N/A,  N=700, Recruiting, 
    Recruiting --> Completed | N=100 --> 43 | Trial primary completion date: Dec 2015 --> Sep 2015 Trial primary completion date: Oct 2015 --> Jan 2016
  • ||||||||||  Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
    Enrollment change, Trial termination, Trial primary completion date, Metastases:  Myocet Plus Endoxan for Older Patients With Breast Cancer (clinicaltrials.gov) -  Oct 7, 2015   
    P2,  N=64, Terminated, 
    Active, not recruiting --> Completed N=46 --> 64 | Recruiting --> Terminated | Trial primary completion date: Feb 2016 --> May 2015; Due to poor accrual
  • ||||||||||  Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
    Trial primary completion date, Metastases:  Myocet Plus Endoxan for Older Patients With Breast Cancer (clinicaltrials.gov) -  Sep 28, 2015   
    P2,  N=46, Recruiting, 
    N=46 --> 64 | Recruiting --> Terminated | Trial primary completion date: Feb 2016 --> May 2015; Due to poor accrual Trial primary completion date: Dec 2014 --> Feb 2016
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Enrollment change, Trial termination:  MRTOX: Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin  (clinicaltrials.gov) -  Sep 18, 2015   
    P2,  N=19, Terminated, 
    Recruiting --> Terminated | Trial primary completion date: Jul 2012 --> Aug 2015; wothdrawal of sponsor N=90 --> 19 | Recruiting --> Terminated; lack of recruitment
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial primary completion date:  ASPER: Early Detection of Broken Hearts in Cancer Patients (clinicaltrials.gov) -  Jul 9, 2015   
    P=N/A,  N=100, Recruiting, 
    N=90 --> 19 | Recruiting --> Terminated; lack of recruitment Trial primary completion date: Jun 2015 --> Dec 2015
  • ||||||||||  Trial initiation date:  Cardiac 3D MRI in Pediatric Cancer Patients (clinicaltrials.gov) -  Jun 29, 2015   
    P=N/A,  N=20, Not yet recruiting, 
    Recruiting --> Active, not recruiting Initiation date: May 2014 --> May 2015
  • ||||||||||  Trial primary completion date:  Breast Cancer Long-term Outcome of Cardiac Dysfunction (clinicaltrials.gov) -  Jun 11, 2015   
    P=N/A,  N=700, Recruiting, 
    Initiation date: May 2014 --> May 2015 Trial primary completion date: Jun 2015 --> Oct 2015
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
    Trial termination, Trial primary completion date, Surgery:  Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma (clinicaltrials.gov) -  Jun 11, 2015   
    P2,  N=100, Terminated, 
    Trial primary completion date: Jun 2015 --> Oct 2015 Active, not recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Dec 2006
  • ||||||||||  Enrollment change, Trial withdrawal:  REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity) (clinicaltrials.gov) -  Apr 14, 2015   
    P=N/A,  N=0, Withdrawn, 
    Active, not recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Dec 2006 N=120 --> 0 | Recruiting --> Withdrawn